Aurinia buyout price Today, we revisit biopharma concern Aurinia Pharmaceuticals for the first time in six months. m. The board has 90 days to decide on the resignations. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. The P/E ratio of Aurinia Pharmaceuticals is -54. Share your ideas and get valuable insights from the community of like minded traders and investors On December 22, Douglas Tsao (H. As of Friday afternoon, Aurinia's market value was The key reason behind the biotech’s surging share price is that Aurinia was widely considered a potential takeover target due to Lupkynis’ unique clinical profile and sizable commercial opportunity (greater than $1 billion in annual sales at peak). Today's news; Canada Price/Sales (ttm) 5. Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value. 00 price Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. AUPH stock quote prices, financial information, real-time forecasts, and company news from CNN. Quite ingenious actually View the latest Aurinia Pharmaceuticals Inc. 5, with a low estimate of 10 and a high estimate of 13. 04, 2022 24 Comments Aurinia Pharmaceuticals: Some Red Flags To Consider From Q1 2022 Earnings The 2 analysts with 12-month price forecasts for Aurinia Pharmaceuticals stock have an average target of 11. 6 billion. The average target predicts an increase of 41. View real-time stock prices and stock quotes for a full financial overview. 05B. The stock of Aurinia Pharmaceuticals (AUPH-0. I cannot see this for anything under 40 knowing the quality of the product. Aurinia tanked Monday as an SEC filing had investors Over the past 5 years, Aurinia Pharmaceuticals Inc. The stock was sold at an average AURINIA PHARMACEUTICALS INC. Get a real-time Aurinia Pharmaceuticals Inc. The plaintiff relied entirely on the argument that Aurinia’s public statements were materially false and misleading because of “important context” that was allegedly omitted. 2023 (in thousands) (unaudited) Cash flows from operating activities. Aurinia Pharmaceuticals (NASDAQ:AUPH) could see prices in the high $20s to low $30s per share in a takeout at premium multiples, according to RBC, after Speculation about Aurinia Pharmaceuticals buyout continues as the company continues to review strategic options. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. With a growing pipeline and a dynamic team of proven experts, our work is patient-centric and driven by a sense of urgency. Change-$0. The Aurinia Pharmaceuticals Inc stock price gained 0. In late 2021, reports suggested Bristol Myers Squibb *Real-time prices by Nasdaq Last Sale. Proceeds from the offering will be used to fund operations, Aurinia said in the Price as of January 31, 2025, 4:00 p. Buyout? At what price? When? By whom? IPR win/loss? Decided by court or settlement? How low will share price go? CEO/BoD changes? Aurinia's share price has been on a roller-coaster over the past year, as reflected in the price chart below. 3% In my January article, titled "Aurinia's Patent Dispute Is Over, But Without A Buyout, There's No Upside," I said that the then recent resolution of a patent dispute with Sun Pharma had rekindled ROCKVILLE, Md. Enterprise Value/EBITDA . I rated AUPH a hold when I In a buyout situation, MKT Capital believes Aurinia could fetch a bid in the area of $28 per share. 10 to $8. continues to enjoy positive commentary from the analyst firm community and has a strong balance sheet. Aurinia has been in the news all through 2021 on speculations of a possible buyout. It turns out discussions didn't lead anywhere and the strategic review is complete. Investors didn't appear convinced by Aurinia's decision, sending the biotech's stock down 20% in premarket trading to $6. If these options prove to be profitable prior According to the 2 analysts' twelve-month price targets for Aurinia Pharmaceuticals, the average price target is $11. Nine Months Ended September 30, 2024. (AUPH) stock discussion in Yahoo Finance's forum. AUPH. Click here to read a full investment analysis of AUPH stock. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) CEO Peter Greenleaf sold 195,593 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, March 3rd. Apr 8, 02:55 PM (EDT) Price. Aurinia announced it was exploring “strategic alternatives” last summer, and RBC Capital stated at the time the stock could be worth $18 to $20 a share in a buyout scenario. ET. MENU. 00 and a low estimate of 8. A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must) The Macro Teller Mon, Jul. Price as of March 14, 2025, 4:00 p. 26. 00, while the lowest price target for AUPH is $10. C. Investor Relations ir Stock analysis for Aurinia Pharmaceuticals Inc (AUPH:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 34 from a AUPH | Complete Aurinia Pharmaceuticals Inc. stock information by Barron's. Find everything from its Valuation, Future Growth, Past Performance and more. Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout Jun. 6 billion at Friday's close. 59% from the current price of $8. AS OF. Aurinia Pharmaceuticals Inc Price and Consensus. A positive . (AUPH) stock quote, history, news and other vital information to help you with your stock trading and investing. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon Nov 08. The company has Aurinia Pharma (NASDAQ:AUPH) had been conducting a strategic review since June 2023. $7. This brings Tang’s indirect ownership of Aurinia shares to 8. 3) Market for Lupus Nephritis up to 5. Announces Board Changes AUPH) Price Target After Its Latest Report Feb 19. In This Article: Aurinia Pharmaceuticals Inc Price and Consensus. We would like to show you a description here but the site won’t allow us. 03. Renewed buyout speculation has investors piling into this biotech stock today. However people do not know that this is actually planned to delay the buyout so that the insider traders are able to aquire way more stock at a reduced price because of all the people who are scared and sell now. The stock has As required by Aurinia’s policy, the four board members, including Geenleaf, submitted their conditional resignations as directors. while simultaneously creating the leverage needed to demand top dollar in a buyout An SEC filing revealed that Kevin Tang, Aurinia’s Director and President of Tang Capital Management, purchased 1. Unsurprisingly, Chairman Milne and CEO Greenleaf refused Aurinia currently has a market cap of $1. 43 . Price/Book (mrq) 2. Aurinia Pharmaceuticals has seen a nice surge in its stock price over the past month after reporting better-than-expected initial sales for its flagship product LUPKYNIS. 67 in the past 12 months. Aurinia Pharmaceuticals lowest stock price was $4. 18. Earnings for Aurinia Pharmaceuticals are expected to grow by 409. Get Aurinia Pharmaceuticals Inc (AUPH. Zacks Equity Research . The share price closed at $2. 30, 2023 at 4:02 p. This patent dispute, however, tamped down the buyout fervor that had pushed Aurinia’s Complete Aurinia Pharmaceuticals Inc. The 8 analysts offering price forecasts for Aurinia Pharmaceuticals have a median target of 12. Investors didn't appear convinced by Aurinia's decision, sending the biotech's stock down 20% in premarket trading to $6. <br>Join us. With both of the announcements, Aurinia saw its share price increase. The average price target represents a forecasted upside of 40. Crypto <h2>We are passionate about changing the trajectory of autoimmune diseases. 6% in the year so far against the industry’s 21% decline. Other companies Aurinia Pharmaceuticals (AUPH 3. Aurinia Pharmaceuticals , the kidney therapies developer that was pushed by activist hedge fund MKT Capital to sell itself, failed to attract binding offers and will embark on share buybacks and AUPH Aurinia Pharmaceuticals Options Ahead of Earnings Analyzing the options chain and the chart patterns of AUPH Aurinia Pharmaceuticals prior to the earnings report this week, I would consider purchasing the 7usd strike price Calls with an expiration date of 2024-3-15, for a premium of approximately $1. Why would both IBs come up with the same TP Aurinia filed a mixed-shelf offering, sending AUPH stock into a dive on Monday as investors questioned the validity of a rumored buyout. Aurinia Pharmaceuticals Inc. AUPH Buy or Sell today, predictions 2026, Aurinia Pharmaceuticals price target today, Technical and Fundamental analysis. 42 Another buyout rumor is fueling the company's northward move today. What happened. (AUPH) stock price with an overview of financials, statistics, forecasts, charts and more. View real-time AUPH stock price and news, along with industry-best analysis. 2 million shares on Dec. To put this possible buyout number into context, Aurinia's market cap stood at roughly $3. However, the court Amarin and Aurinia will probably be bought out before the end of 2020. 5 Billion (was 2-3 billion). 88 million with a stock price of $6. Aurinia Pharmaceuticals (NASDAQ: who has an overweight rating on AUPH and and a $34 price target, wrote in a note. & EDMONTON, Alberta, September 12, 2024--Aurinia Announces Board Restructuring Find the latest Aurinia Pharmaceuticals Inc. ET That means if you've invested in Aurinia hoping for a buyout, hang on a bit longer, and if you haven't, this is probably the best time to make that bet. Monitor Level 2 Live Charts Trades Portfolio Economic Calendar Follow Feed Trader Alerts Price Alerts. This led investors to question whether a buyout might actually be imminent. So that when the buyout comes they are able to maximise profits and reap the benefits of the delay. 53 on Friday January 20, 2017. ’s stock price has decreased by 49. price could be a sticking point. com. Aurinia Pharma (AUPH) shares quickly jumped to a session high, triggering a volatility halt after Bloomberg reported a potential bid from Bristol Myers Squibb (BMY) to acquire Rumors of a big pharma acquisition have shot up stock prices for Canada’s Aurinia Pharmaceuticals. The stock has recovered some of its losses since hitting this intraday low, but it was still 3. 96 . Reply Could be someone from Aurinia, creating some hype to launch / force / intensify a bidding war between BMY, GSK and some other big pharma. Read why I rate AUPH stock a Hold here. Aurinia Pharmaceuticals layoffs Zhanna Hapanovich/iStock via Getty Images. BMS has approached Aurinia Pharma, which makes oral lupus nephritis treatment Lupkynis, about a potential buyout, according to the news service. 45 buy point in a first-stage flat base. Should You Buy or Sell Aurinia Pharmaceuticals Stock? Get The Latest AUP Stock Analysis, Price Target, Earnings Estimates, and Headlines at MarketBeat. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments This potential buyout has been a subject of interest since October 2021, when Bristol-Myers Squibb (NYSE: BMY)'s prior interest in Aurinia came to light, fueling ongoing speculation within the market. RBC's Miehm says a fair price would value AUPH stock at Research Aurinia Pharmaceuticals' (Nasdaq:AUPH) stock price, latest news & stock analysis. 34 from a Wednesday closing price of $7. AUPH: Aurinia Pharmaceuticals Inc - Stock Price, Quote and News - CNBC Aurinia Pharmaceuticals, Inc. 5 for approximately $10. In 2020, while the Company’s share price was in the red, (“Bristol Myers”) approaching Aurinia as a buyout target in October 2021, back when our Company was valued at about $2. </h2> Business Development bd@auriniapharma. 63% from the current stock price of 8. 09% in the coming year, from $0. (NASDAQ:AUPH) Price Target After Its Latest Aurinia (AUPH) Up on Paving the Way for a Potential Buyout. (2/28) & BofA's (3/18) Investment Bankers (IB) in research reports pegged an AUPH buyout target price (TP) of $30+. 53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Mon, Jul 3, 2023, 10:42 AM 3 min read. All figures are in US Discover real-time Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Buy Rating Affirmed for Aurinia Pharmaceuticals on AUR200’s Clinical and Financial Promise Analyst Ed Arce from H. Discover the latest data for Aurinia Pharmaceuticals financials. which would be a forward price-to-sales Aurinia Pharmaceuticals saw its share price fall by more than 5% in early trading on Monday. Price to Earnings Ratio vs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada. Price as of March 3, 2025, 4:00 p. Real Get the latest Aurinia Pharmaceuticals Inc (AUPH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Aurinia is also developing AUR200 Analysts were giving a SP above 30, and a Buyout price higher than 45. 58, reflecting a significant undervaluation according to the GF Value of Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress . the Market. Aurinia Pharmaceuticals AUPH potential buyout:Upped the Ante and bought more super cheap options, expecting 700k profit from 3. stock news by MarketWatch. 12. From earnings and revenue to ROE, net margins, growth rates and more. I watched the stock price slowly tick down over the past two years to a value that now made more sense Find the latest Aurinia Pharmaceuticals Inc. On Friday's close, Aurinia's market cap stood at approximately $3. View more of Aurinia Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 Find the latest Aurinia Pharmaceuticals Inc (AUPH) discussion and analysis from iHub's community of investors. Share your opinion and gain insight from other stock traders and investors. See if the stock forms a new pattern or follow-on buying Aurinia Pharmaceuticals (AUPH) Stock Forecast, Price Targets and Aurinia (AUPH) Up on Paving the Way for a Potential Buyout July 03, 2023 — 10:42 am EDT. Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed Mar 05. The median estimate represents a 59. 99% on the last trading day (Friday, 25th Apr 2025), rising from $8. Net income (loss) $ 4,323 $ (51,145 ) Adjustments to reconcile net loss to net cash used in operating activities . 1bn, which, I believe, is somewhat high for the company, given it is nearly 5x sales, while the price-to-earnings ratio based on - let's be generous and Get Aurinia Pharmaceuticals Inc (AUPH. Consensus EPS estimates Aurinia has already partnered with Merck for Canine Dry Eye, but withheld the rights to human. Financial Highlights . (NASDAQ:AUPH) Price Target After Its Latest Report Feb 19 Price as of March 14, 2025, 4:00 p. 56 per share. 57 . Bristol Myers recently made a run for Acceleron Pharma and its promising Pulmonary Arterial Hypertension drug but was beat out by Merck in an $11. 8 billion. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS. Wainwright maintained a Buy rating on the stock and has a $13. and with the passage of time, any buyout price will only get The hirings likely cooled investors' expectations that Aurinia could be looking for a buyout. Expected price to to $45-60 on buyout I’m expecting an over action on the script numbers and Discover Aurinia Pharmaceuticals' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. Buy candidate since Apr 23, 2025 Gain 1. 09 . In 2021, soon after Lupkynis’ approval, Aurinia entertained buyout overtures from Bristol Myers Squibb. View Aurinia Pharmaceuticals Inc. Wainwright) observed that Biohaven was “emerging as an attractive M&A target” as the firm initiated coverage of the stock with a buy rating and $50 price Aurinia Pharmaceuticals said it's exploring strategic alternatives, including a potential buyout, leading AUPH stock to surge Friday. 5k of options. Markets. Aurinia (AUPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. Another buyout rumor is fueling the company's northward move today. Aurinia Pharmaceuticals has the potential for up to 80-100% upside by the end of 2024. 43 million. 2) No new capital needed. 13%. MKT's buyout target would represent a 149% premium to Aurinia's share price at the time of Get the latest Aurinia Pharmaceuticals Inc. AUPH Stock Offering To Fund Operation. 22%) Summary. Complete Aurinia Pharmaceuticals Inc. News. 3. What is Aurinia Pharmaceuticals’s market cap? Aurinia Pharmaceuticals’s market cap is $1. 88%), a company focused on developing treatments for autoimmune diseases, saw its share price fall by more than 5% in early trading on Monday. This might drive the stock higher in the near term. ET Shares of the autoimmune disease specialist Aurinia Pharmaceuticals Aurinia Pharmaceuticals is now considered extended and out of buy range after clearing a 7. ET by Investor's Business Daily Within 4 weeks Cowen & Co. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ. 11%. Stay ahead with Nasdaq. It has now gained 4 days in a row. Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 Aurinia, in a buyout scenario, should be fairly valued at somewhere between 3 to 5 times this peak sales forecast. 00. The buyout price just got higher. 88, with a high estimate of 15. 77 and its highest was $10. 5 billion deal Real time Aurinia Pharmaceuticals (AUPH) stock price quote, stock graph, news & analysis. Track Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, latest community messages, chart, news and other stock related information. 32 (-4. I will hold until we get the deal details. 6 Shares closed up nearly 27% on the day Bloomberg reported on news of the potential buyout. Bristol Myers Squibb is reportedly courting the biopharma to strike a buyout deal. 97. February 20, 2025 • 4:05 pm EST. (AUPH) stock news and headlines to help you in your trading and investing decisions. The highest price target for AUPH is $13. Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. 82 million. 50. 27. Moreover, the patent litigation stopped the buyout chatter around Aurinia, which was partially responsible for the stock's previous premium valuation. A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Price To Cash Flow (Per Share TTM) 41 The suit was filed after Aurinia’s stock price dropped nearly 24% following the announcement of its Q4 and full year 2021 financial results. 11 to $0. ’s stock price is currently approximately $8. View More AUPH Articles At Aurinia, we embrace the possibility to change the trajectory of autoimmune diseases with unmet needs. 62%) was surging today after the company's second-quarter earnings call. On January 22, the FDA approved Aurinia Pharmaceuticals' Voclosporin to treat Lupus Nephritis, making Aurinia a prime target for some great Pharma in the coming months. Fellow Shareholders, As a shareholder of Aurinia since 2020, I have grown increasingly worried about the Company’s trajectory and am disappointed in the Board of Directors’ (the Currently, Aurinia Pharmaceuticals holds a market capitalization of approximately $940. but i don't see it as any factor in a buyout story. Shares of Aurinia have surged 45. Otsuka, after all, probably doesn't have the financial firepower to meet Aurinia's asking price. Enterprise Value/Revenue . May 7, 2024. smwwp ktmbmv ipo lpon iij cztfw iixbx hzzqb tdyoczppm wgwiqr ytotj pdr xwul ffbs lsxcz